New drug duo offers hope for Hard-to-Treat lymphoma
NCT ID NCT04572763
First seen Jan 09, 2026 · Last updated Jun 12, 2026 · Updated 26 times
Summary
This study tests a combination of two drugs, copanlisib and venetoclax, in about 48 adults with diffuse large B-cell lymphoma that has come back or not responded to prior treatment. The goal is to find the safest dose and see how well the drugs shrink tumors. Participants must have already tried certain advanced therapies or be unable to receive them.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Cancer Center
Duarte, California, 91010, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Siteman Cancer Center at Washington University
St Louis, Missouri, 63110, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.